BioScience Laboratories Announces Testing Capabilities To Support Approved Health Canada Guidance Document For Human-Use Antiseptic Drugs
BioScience Laboratories announces efficacy and safety testing capabilities to support Health Canada's guidance document Human-Use Antiseptic Drugs.

BOZEMAN, MT, December 31, 2009 /24-7PressRelease/ -- BioScience Laboratories announces efficacy and safety testing capabilities to support Health Canada's guidance document Human-Use Antiseptic Drugs finalized on December 2, 2009. BioScience Laboratories actively participated in the development and revision of this document. The organization's Clinical and In-Vitro Laboratories have the training and experience to conduct the testing methods in accordance with CEN, ASTM, and ICH guidelines, as required in this document to show product efficacy and safety. BioScience Laboratories' GCP and GLP compliant quality system ensures that the testing documentation generated will meet Health Canada's requirements for submission to support product efficacy and safety claims.

For more information on BioScience Laboratories' capabilities to perform the testing outlined in the Health Canada Human-Use Antiseptic Drugs guidance document, contact:

John Dyba
Senior Account Executive
1-877-858-2754
jdyba@biosciencelabs.com
http://www.biosciencelabs.com

Press Release Contact Information:

John Dyba
BioScience Laboratories
Senior Account Executive
300 N. Willson, Suite 1
Bozeman, MT
USA 59715
Voice: 1-877-858-2754
Fax: 406-586-7930
Website: Visit Our Website